One of the stories that has stood out over the last few years in breast cancer treatment was the FDA’s approval in 2015 of the drug palbociclib (Ibrance) for treatment of hormone receptor-positive metastatic breast cancer.
This year, there have been several new developments in targeted therapies for hormone-receptor positive breast cancer. Continue reading
What’s the latest “need to know” news in cancer research? In this post, I’ll briefly review several of the most interesting cancer research stories that have been in the news this fall.
These are a few of the recent stories that seem to have the greatest potential impact, at least from my perspective, and that I know I’ll want to follow as they develop further. Continue reading
